Glasgow 2018—Comparable viral decay with dolutegravir plus lamivudine (DTG + 3TC) vs dolutegravir-based triple therapy1

Viral decay in A5353, a pilot study of DTG + 3TC

In A5353, a pilot study of DTG + 3TC in which 30% of participants had pretreatment viral loads (VL) of 100,000 copies/mL to 500,000 copies/mL, viral decay was determined in comparison to the decay in the DTG (50 mg) + 2 NRTIs arms of the SPRING-1 and SINGLE studies. Change in VL from baseline (pretreatment) was calculated for time points shared by A5353 (N=120), SPRING-1 (N=51), and SINGLE (N=417)—ie, study entry (Week 0), and Weeks 2, 4, 8, 12, 16 and 24.

The VL change from baseline with a 2-drug regimen was non-inferior to a 3-drug regimen (P<0.001). In the decay model, the 2-drug regimen was associated with a faster initial decay rate compared with a 3-drug regimen, and comparable even in individuals with higher pretreatment VL up to 500,000 copies/mL.1

Access the full abstract.

  1. Gillman J, Janulis P, Gulick R, et al. Comparable viral decay with dolutegravir plus lamivudine (DTG + 3TC) vs dolutegravir-based triple therapy. Presented at: HIV Drug Therapy Glasgow 2018; October 28-31, 2018; Glasgow, UK.

UK/DTGP/0027/18 - November 2018